Sepracor taps Adams as CEO

Share this article:
Sepracor named Adrian Adams CEO, replacing Timothy Barberich, who was elected executive chairman of the company’s board of directors. Adams appointment had been anticipated since his hiring as COO on March 1. Adams, who will retain title of president, was previously CEO at Kos Pharmaceuticals from 2002 until the acquisition of the company by Abbott Laboratories in December 2006 for $3.7 billion. Adams is a 30-year veteran of the pharmaceutical industry with experience in national and international product marketing, R&D, sales, business development and general management with companies including ICI, SmithKline Beecham and Novartis.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.